

## Infliximab:

### **Remicade®; Inflectra™; Renflexis™; Avsola™ (Intravenous)**

Document Number: IC-0104

**Last Review Date: 08/03/2021**

**Date of Origin: 07/20/2010**

**Dates Reviewed: 09/2010, 12/2012, 2/2011, 03/2011, 06/2011, 09/2011, 10/2011, 12/2011, 03/2012, 06/2012, 09/2012, 11/2012, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 06/2015, 09/2015, 12/2015, 03/2016, 06/2016, 09/2016, 12/2016, 03/2017, 06/2017, 09/2017, 12/2017, 03/2018, 06/2018, 10/2018, 04/2019, 07/2019, 07/2020, 08/2021**

#### **I. Length of Authorization**

Coverage will be provided for 6 months and may be renewed unless otherwise specified.

- Therapy for the Management of Immune-Checkpoint Inhibitor Related Toxicity and GVHD may not be renewed.

#### **II. Dosing Limits**

##### **A. Quantity Limit (max daily dose) [NDC Unit]:**

|   |
|---|
| <b><u>Loading Dose:</u></b> <ul style="list-style-type: none"><li>– Remicade 100 mg single-use vial: 6 vials at weeks 0, 2, 6 (18 vials total)</li><li>– Inflectra 100 mg single-use vial: 6 vials at weeks 0, 2, 6 (18 vials total)</li><li>– Renflexis 100 mg single-use vial: 6 vials at weeks 0, 2, 6 (18 vials total)</li><li>– Avsola 100 mg single-use vial: 6 vials at weeks 0, 2, 6 (18 vials total)</li></ul> |
| <b><u>Maintenance Dose:</u></b> <ul style="list-style-type: none"><li>– Remicade 100 mg single-use vial: 10 vials every 4 weeks</li><li>– Inflectra 100 mg single-use vial: 10 vials every 4 weeks</li><li>– Renflexis 100 mg single-use vial: 10 vials every 4 weeks</li><li>– Avsola 100 mg single-use vial: 10 vials every 4 weeks</li></ul>   |

##### **B. Max Units (per dose and over time) [HCPCS Unit]:**

|  |
|--|
| <b><u>Loading Dose:</u></b><br><b>Rheumatoid Arthritis (RA)</b> <ul style="list-style-type: none"><li>• 40 billable units at weeks 0, 2, 6</li></ul> <b>All other indications (except management of immune checkpoint inhibitor toxicity)</b> <ul style="list-style-type: none"><li>• 60 billable units at weeks 0, 2, 6</li></ul> <b>Acute GVHD</b> <ul style="list-style-type: none"><li>• 10 billable units at weeks 0, 1, 2, 3</li></ul> <b>Management of immune checkpoint inhibitor toxicity</b> |
|--|

|   |
|---|
| <ul style="list-style-type: none"> <li>• 60 billable units at weeks 0,2</li> </ul> <p><b><u>Maintenance Dose:</u></b></p> <p><b>Rheumatoid Arthritis (RA)</b></p> <ul style="list-style-type: none"> <li>• 100 billable units every 4 weeks</li> </ul> <p><b>Crohn's Disease/Ulcerative Colitis</b></p> <ul style="list-style-type: none"> <li>• 100 billable units every 8 weeks</li> </ul> <p><b>Ankylosing Spondylitis</b></p> <ul style="list-style-type: none"> <li>• 60 billable units every 6 weeks</li> </ul> <p><b>All other indications (except management of immune checkpoint inhibitor toxicity)</b></p> <ul style="list-style-type: none"> <li>• 60 billable units every 8 weeks</li> </ul> |
|---|

### III. Initial Approval Criteria <sup>1-4</sup>

Coverage is provided in the following conditions:

- Patient has been evaluated and screened for the presence of hepatitis B virus (HBV) prior to initiating treatment; **AND**
- Physician has assessed baseline disease severity utilizing an objective measure/tool; **AND**
- Patient is up to date with all vaccinations, in accordance with current vaccination guidelines, prior to initiating therapy; **AND**
- Patient is at least 18 years of age (unless otherwise specified); **AND**

#### Universal Criteria <sup>1-4</sup>

- Patient has been evaluated and screened for the presence of latent tuberculosis (TB) infection prior to initiating treatment and will receive ongoing monitoring for presence of TB during treatment; **AND**
- Patient does not have an active infection, including clinically important localized infections; **AND**
- Must not be administered concurrently with live vaccines or therapeutic infectious agents (i.e., BCG bladder instillation for bladder cancer, etc.); **AND**
- Patient is not on concurrent treatment with another TNF-inhibitor, biologic response modifier or other non-biologic agent (i.e., apremilast, tofacitinib, baricitinib, etc.); **AND**
- Will not be used in patients with moderate or severe heart failure (i.e., New York Heart Association [NYHA] Functional Class III/IV) [Note: Only applies when doses >5mg/kg are used]; **AND**

#### Crohn's Disease † ⊕ <sup>11,13,23,38,75,76,77,78</sup>

- Must be prescribed by, or in consultation with, a specialist in gastroenterology; **AND**
- Documented moderate to severe disease; **AND**
- Documented failure, contraindication, or ineffective response at maximum tolerated doses to a minimum (3) month trial of corticosteroids or immunomodulators (e.g., azathioprine, 6-mercaptopurine, or methotrexate)

#### Pediatric Crohn's Disease † ⊕ <sup>13,23</sup>

**INFLIXIMAB (Remicade®; Inflectra™; Renflexis™; Avsola™)**  
**Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management



- Must be prescribed by, or in consultation with, a specialist in gastroenterology; **AND**
- Patient is at least 6 years of age; **AND**
- Documented moderate to severe disease; **AND**
- Documented failure, contraindication, or ineffective response at maximum tolerated doses to a minimum (3) month trial of corticosteroids or immunomodulators (e.g., azathioprine, etc.)

#### **Ulcerative Colitis †<sup>20,27,77</sup>**

- Must be prescribed by, or in consultation with, a specialist in gastroenterology; **AND**
- Documented moderate to severe disease; **AND**
- Documented failure, contraindication, or ineffective response at maximum tolerated doses to a minimum (3) month trial of corticosteroids or immunomodulators (e.g., azathioprine, 6-mercaptopurine, or methotrexate)

#### **Pediatric Ulcerative Colitis † ⊕<sup>20</sup>**

- Must be prescribed by, or in consultation with, a specialist in gastroenterology; **AND**
- Patient is at least 6 years of age; **AND**
- Documented moderate to severe disease; **AND**
- Documented failure, contraindication, or ineffective response at maximum tolerated doses to a minimum (3) month trial of corticosteroids or immunomodulators (e.g., azathioprine, etc.)

#### **Fistulizing Crohn's Disease †<sup>38,76</sup>**

- Must be prescribed by, or in consultation with, a specialist in gastroenterology; **AND**
- Patient has at least one or more draining fistulas (i.e., enterovesical, enterocutaneous, enteroenteric, or enterovaginal fistulas) for at least 3 months

#### **Rheumatoid Arthritis (RA) †<sup>5,16,1829,30,74</sup>**

- Must be prescribed by, or in consultation with, a specialist in rheumatology; **AND**
- Documented moderate to severe disease; **AND**
- Patient has had at least a 3 month trial and failed previous therapy with ONE oral disease modifying anti-rheumatic agent (DMARD) such as methotrexate, azathioprine, auranofin, hydroxychloroquine, penicillamine, sulfasalazine, leflunomide, etc.; **AND**
- Used in combination with methotrexate (MTX) unless contraindicated

#### **Psoriatic Arthritis †<sup>15,17,39,41,71</sup>**

- Must be prescribed by, or in consultation with, a specialist in dermatology or rheumatology; **AND**
- Documented moderate to severe active disease; **AND**

- For patients with predominantly axial disease OR active enthesitis, a trial and failure of at least a 4-week trial of ONE (1) non-steroidal anti-inflammatory agents (NSAIDs), unless use is contraindicated; **OR**
- For patients with peripheral arthritis or dactylitis, a trial and failure of at least a 3 month trial of ONE oral disease-modifying anti-rheumatic agent (DMARD) such as methotrexate, azathioprine, sulfasalazine, hydroxychloroquine, etc.

### **Ankylosing Spondylitis †<sup>6,19,73</sup>**

- Must be prescribed by, or in consultation with, a specialist in rheumatology; **AND**
- Documented active disease; **AND**
- Patient had an adequate trial and failure of at least TWO (2) non-steroidal anti-inflammatory agents (NSAIDs) over 4 weeks (in total), unless use is contraindicated

### **Plaque Psoriasis †<sup>7,14,32,33,40,41,69,70,79</sup>**

- Must be prescribed by, or in consultation with, a specialist in dermatology or rheumatology; **AND**
- Documented moderate to severe plaque psoriasis for at least 6 months with at least one of the following:
  - Involvement of at least 3% of body surface area (BSA); **OR**
  - Psoriasis Area and Severity Index (PASI) score of 10 or greater; **OR**
  - Incapacitation or serious emotional consequences due to plaque location (i.e., hands, feet, head and neck, genitalia, etc.) or with intractable pruritis; **AND**
- Patient did not respond adequately (or is not a candidate) to a 4 week minimum trial of topical agents (i.e., anthralin, coal tar preparations, corticosteroids, emollients, immunosuppressives, keratolytics, retinoic acid derivatives, and/or vitamin D analogues, etc.); **AND**
- Patient did not respond adequately (or is not a candidate) to a 3 month minimum trial of at least one non-biologic systemic agent (i.e., immunosuppressives, retinoic acid derivatives, and/or methotrexate, etc.); **AND**
- Patient did not respond adequately (or is not a candidate\*) to a 3 month minimum trial of phototherapy (i.e., psoralens with UVA light [PUVA] or UVB with coal tar or dithranol, etc.)

### **Uveitis Associated with Behçet's Syndrome ‡<sup>8-10,21,22,34,35</sup>**

- Must be prescribed by, or in consultation with, a specialist in rheumatology or ophthalmology; **AND**
- Patient's disease is refractory to immunosuppressive therapy (e.g., corticosteroids, etc.); **AND**
- Patient had an inadequate response to a self-administered biologic therapy (e.g., adalimumab)

### Graft Versus Host Disease (GVHD) † 43,65,66

- Patient has received a hematopoietic stem cell transplant; **AND**
- Used for steroid-refractory acute GVHD; **AND**
- Used in combination with systemic corticosteroids as additional therapy following no response to first-line therapies

### Management of Immune Checkpoint Inhibitor Related Toxicity † 36,37,43

- Patient has been receiving therapy with an immune checkpoint inhibitor (e.g., nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab, ipilimumab, dostarlimab, etc.); **AND**
- Patient has one of the following toxicities related to their immunotherapy:
  - Suspected myocarditis if no improvement after 24-hours of starting pulse-dose methylprednisolone
  - Moderate (grade 2) to severe (grade 3-4) diarrhea or colitis
  - Severe (grade 3-4) pneumonitis refractory to methylprednisolone after 48 hours of therapy
  - Severe (grade 3) or life-threatening (grade 4) acute kidney injury or elevated serum creatinine that is refractory to at least 1 week of therapy with corticosteroids
  - Uveitis (grade 3-4) that is refractory to high-dose systemic corticosteroids
  - Severe inflammatory arthritis as additional disease-modifying therapy if symptoms do not improve within 1 week after starting high-dose corticosteroids or if unable to taper corticosteroids by week 2
  - Moderate, severe, or life-threatening steroid-refractory myalgias or myositis

#### \*Examples of contraindications to phototherapy (PUVA or UVB) include the following: 67,68

- Xeroderma pigmentosum
- Pregnancy or lactation (PUVA only)
- Lupus Erythematosus
- History of one of the following: photosensitivity diseases (e.g., chronic actinic dermatitis, solar urticaria), melanoma, non-melanoma skin cancer, extensive solar damage (PUVA only), treatment with arsenic or ionizing radiation
- Immunosuppression in an organ transplant patient (UVB only)
- Photosensitizing medications (PUVA only)
- Severe liver, renal, or cardiac disease (PUVA only)

† FDA Approved Indication(s); ‡ Compendia recommended indication(s); Ⓢ Orphan Drug

## IV. Renewal Criteria 1-4

Coverage can be renewed based upon the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: severe hypersensitivity reactions, malignancy (e.g., lymphoma including hepatosplenic T-Cell lymphoma, skin cancers, cervical cancer, etc.), significant hematologic

**INFLIXIMAB (Remicade®; Inflectra™; Renflexis™; Avsola™)**  
**Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management

abnormalities, serious infections (i.e., TB, serious fungal infections, HBV reactivation, etc.), cerebrovascular accidents, cardiotoxicity/heart failure, neurotoxicity, hepatotoxicity, lupus-like syndrome, demyelinating disease, etc.; **AND**

### **Crohn's Disease** <sup>23</sup>

- Disease response as indicated by improvement in signs and symptoms compared to baseline such as endoscopic activity, number of liquid stools, presence and severity of abdominal pain, presence of abdominal mass, body weight compared to IBW, hematocrit, presence of extra-intestinal complications, tapering or discontinuation of corticosteroid therapy, use of anti-diarrheal drugs, and/or an improvement on a disease activity scoring tool [e.g. an improvement on the Crohn's Disease Activity Index (CDAI) score or the Harvey-Bradshaw Index score].

### **Pediatric Crohn's Disease** <sup>23</sup>

- Disease response as indicated by improvement in signs and symptoms compared to baseline such as endoscopic activity, number of liquid stools, presence and severity of abdominal pain, presence of abdominal mass, body weight compared to IBW, hematocrit, presence of extra-intestinal complications, tapering or discontinuation of corticosteroid therapy, use of anti-diarrheal drugs and/or an improvement on a disease activity scoring tool [e.g. an improvement on the Pediatric Crohn's Disease Activity Index (PCDAI) score or the Harvey-Bradshaw Index score].

### **Ulcerative Colitis** <sup>24-26</sup>

- Disease response as indicated by improvement in signs and symptoms compared to baseline such as stool frequency, rectal bleeding, and/or endoscopic activity, tapering or discontinuation of corticosteroid therapy, and/or an improvement on a disease activity scoring tool [e.g. an improvement on the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score or the Mayo Score].

### **Pediatric Ulcerative Colitis** <sup>24-27</sup>

- Disease response as indicated by improvement in signs and symptoms compared to baseline such as stool frequency, rectal bleeding, and/or endoscopic activity, tapering or discontinuation of corticosteroid therapy, and/or an improvement on a disease activity scoring tool [e.g. an improvement on the Pediatric Ulcerative Colitis Activity Index (PUCAI) score or the Mayo Score].

### **Fistulizing Crohn's Disease** <sup>23</sup>

- Disease response as indicated by improvement in signs and symptoms compared to baseline such as a reduction in number of enterocutaneous fistulas draining upon gentle compression, and/or an improvement on a disease activity scoring tool [e.g. an improvement on the Crohn's Disease Activity Index (CDAI) score or the Harvey-Bradshaw Index score].

### **Psoriatic Arthritis** <sup>28,72</sup>

- Disease response as indicated by improvement in signs and symptoms compared to baseline such as the number of tender and swollen joint counts and/or an improvement on a disease activity scoring tool [e.g. defined as an improvement in at least 2 of the 4 Psoriatic Arthritis Response Criteria (PsARC), 1 of which must be joint tenderness or swelling score, with no worsening in any of the 4 criteria].

## Rheumatoid Arthritis <sup>29-31</sup>

- Disease response as indicated by improvement in signs and symptoms compared to baseline such as the number of tender and swollen joint counts, reduction of C-reactive protein, improvement of patient global assessment, and/or an improvement on a disease activity scoring tool [e.g. an improvement on a composite scoring index such as Disease Activity Score-28 (DAS28) of 1.2 points or more or a  $\geq 20\%$  improvement on the American College of Rheumatology-20 (ACR20) criteria].

## Ankylosing Spondylitis <sup>12</sup>

- Disease response as indicated by improvement in signs and symptoms compared to baseline such as total back pain, physical function, morning stiffness, and/or an improvement on a disease activity scoring tool [e.g.  $\geq 1.1$  improvement on the Ankylosing Spondylitis Disease Activity Score (ASDAS) or an improvement of  $\geq 2$  on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)].

## Plaque Psoriasis <sup>32-33</sup>

- Disease response as indicated by improvement in signs and symptoms compared to baseline such as redness, thickness, scaliness, and/or the amount of surface area involvement (a total BSA involvement  $\leq 1\%$ ), and/or an improvement on a disease activity scoring tool [e.g. a 75% reduction in the PASI score from when treatment started (PASI 75) or a 50% reduction in the PASI score (PASI 50) and a four-point reduction in the DLQI from when treatment started].

## Uveitis Associated with Behçet's Syndrome <sup>34-35</sup>

- Disease response as indicated by an improvement in signs and symptoms compared to baseline [e.g. reduction in inflammation and/or lesions, dose reduction of oral glucocorticoids and/or immunosuppressive agents, improvement in vitreous haze, improvement in best corrected visual acuity (BCVA), disease stability and/or reduced rate of decline].

## Acute GVHD ‡

- May not be renewed (*Note: Requests for continued therapy beyond four doses will be reviewed on a case-by-case basis.*)

## Management of Immune Checkpoint Inhibitor related Toxicity ‡

- May not be renewed.

## V. Dosage/Administration <sup>1-4,36,37,42</sup>

| Indication                           | Loading Doses              | Maintenance Dosing               | Maximum Dose & Frequency     |
|--------------------------------------|----------------------------|----------------------------------|------------------------------|
| Rheumatoid Arthritis                 | 3 mg/kg at weeks 0, 2, & 6 | 3 mg/kg every 8 weeks thereafter | Up to 10 mg/kg every 4 weeks |
| Ankylosing Spondylitis               | 5 mg/kg at weeks 0, 2, & 6 | 5 mg/kg every 6 weeks thereafter | 5 mg/kg every 6 weeks        |
| Crohn's Disease & Ulcerative Colitis | 5 mg/kg at weeks 0, 2, & 6 | 5 mg/kg every 8 weeks thereafter | Up to 10 mg/kg every 8 weeks |

**INFLIXIMAB (Remicade<sup>®</sup>; Inflectra<sup>™</sup>; Renflexis<sup>™</sup>; Avsola<sup>™</sup>)**  
**Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management

|  |                            |                                  |                       |
|--|----------------------------|----------------------------------|-----------------------|
| Psoriatic Arthritis, Plaque Psoriasis, Behçet's Uveitis    | 5 mg/kg at weeks 0, 2, & 6 | 5 mg/kg every 8 weeks thereafter | 5 mg/kg every 8 weeks |
| Management of Immune Checkpoint Inhibitor Related Toxicity | 5 mg/kg at weeks 0,2       | N/A                              | N/A                   |
| Acute GVHD   | 10 mg/kg at week 0,1,2 & 3 | N/A                              | N/A                   |

- Dose escalation (up to the maximum dose and frequency specified above) may occur upon clinical review on a case by case basis provided that the patient has:
  - Shown an initial response to therapy; **AND**
  - Received the three loading doses at the dose AND interval specified above; **AND**
  - Received a minimum of one maintenance dose at the dose AND interval specified above; **AND**
  - Responded to therapy (by treatment week 16) with subsequent loss of response; **AND**
  - Dose escalation may either increase the dose OR decrease the interval provided it does not exceed the following limits:
    - Dose increase by no more than 2.5 mg/kg; **OR**
    - Interval decrease by no more than 2 weeks

Note:

- Prior to escalating doses a patient's neutralizing IFX-antibodies should be assessed and addition of a DMARD (e.g., thiopurine or MTX), if not already on such therapy, should be considered.
- Criteria for disease-specific response to therapy are noted in section IV. Patients with moderate to severe heart failure (NYHA Functional Class III/IV; LVEF  $\leq$ 35%) should not receive doses in excess of 5 mg/kg.

## VI. Billing Code/Availability Information

HCPCS Code:

- J1745 – Injection, infliximab, excludes biosimilar, 10 mg; 1 billable unit = 10 mg
- Q5103 – Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg; 1 billable unit = 10 mg
- Q5104 – Injection, infliximab-abda, biosimilar, (renflexis), 10 mg; 1 billable unit = 10 mg
- Q5121 – Injection, infliximab-axxq, biosimilar, (avsola), 10 mg; 1 billable unit=10 mg

NDC:

- Remicade 100 mg single-use vial for injection: 57894-0030-xx
- Inflectra 100 mg single-use vial: 00069-0809-xx
- Renflexis 100 mg single-use vial: 00006-4305-xx
- Avsola 100 mg single-use vial for injection: 55513-0670-xx

## VII. References

1. Remicade [package insert]. Horsham, PA; Janssen Biotech, Inc; May 2020. Accessed July 2021.
2. Inflectra [package insert]. Yeonsu-gu, Incheon, Republic of Korea; CELLTRION, Inc; June 2021. Accessed July 2021.

**INFLIXIMAB (Remicade®; Inflectra™; Renflexis™; Avsola™)**  
**Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management



3. Renflexis [package insert]. Yeonsu-gu, Incheon, Republic of Korea; Samsung Bioepis Co., Ltd; February 2021. Accessed July 2021.
4. Avsola [package insert]. Thousand Oaks, CA; Amgen, Inc; December 2019. Accessed July 2021.
5. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 2015 Nov 6. doi: 10.1002/acr.22783.
6. Ward MM, Deodhar, A, Akl, EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatol*. 2015 Sep 24. doi: 10.1002/art.39298.
7. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. *J Am Acad Dermatol* 2007;56:31e1-15.
8. Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, Cimino L, Gini G, Lenzetti I, Cantini F. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. *Rheumatology (Oxford)*. 2007 Jul;46(7):1161-4. Epub 2007 May 3.
9. Giardina A, Ferrante A, Ciccia F, et al. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behcet's disease refractory to standard immunosuppressive drugs. *Rheumatol Int* 2011;31:33–37.
10. Okada A, Goto H, Ohno S, et al. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. *Arch Ophthalmol* 2012;130(5):592-598.
11. Lichtenstein GR, Loftus EV, Isaacs KL, et al. American College of Gastroenterology. Clinical Guideline: Management of Crohn's disease in adults. *Am J Gastroenterol*. 2018;113:481-517.
12. Kornbluth, A, Sachar, DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol*. 2010 Mar;105(3):501-23.
13. Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. *Gastroenterology*. 2013 Dec;145(6):1459-63. doi: 10.1053/j.gastro.2013.10.047.
14. Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. *Arch Dermatol*. 2012 Jan;148(1):95-102.
15. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. *J Am Acad Dermatol* 2008 May;58(5):851-64.
16. National Institute for Health and Clinical Excellence (NICE). Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Aug. 73 p. (Technology appraisal guidance; no. 195)

**INFLIXIMAB (Remicade®; Inflectra™; Renflexis™; Avsola™)**  
**Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management

17. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Ann Rheum Dis*. 2015 Dec 7. pii: annrheumdis-2015-208337. doi: 10.1136/annrheumdis-2015-208337.
18. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*. 2017 Mar 6. pii: annrheumdis-2016-210715.
19. Van Der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis* doi:10.1136/annrheumdis-2016-210770.
20. Harbord M, Eliakim R, Bettenworth D, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. *J Crohns Colitis*. 2017 Jan 28. doi: 10.1093/ecco-jcc/jjx009.
21. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. *Am J Ophthalmol*. 2000 Oct;130(4):492-513.
22. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. *Ophthalmology*. 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.ophtha.2013.09.048.
23. National Institute for Health and Care Excellence. NICE 2012. Crohn's Disease: Management. Published 10 October 2012. Clinical Guideline [CG152]. <https://www.nice.org.uk/guidance/cg152/resources/crohns-disease-management-pdf-35109627942085> .
24. Lewis JD, Chuai S, Nessel L, et al. Use of the Non-invasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis. *Inflamm Bowel Dis*. 2008 Dec; 14(12): 1660–1666. doi: 10.1002/ibd.20520
25. Paine ER. Colonoscopic evaluation in ulcerative colitis. *Gastroenterol Rep (Oxf)*. 2014 Aug; 2(3): 161–168.
26. Walsh AJ, Bryant RV, Travis SPL. Current best practice for disease activity assessment in IBD. *Nature Reviews Gastroenterology & Hepatology* 13, 567–579 (2016) doi:10.1038/nrgastro.2016.128
27. Kornbluth, A, Sachar, DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol*. 2010 Mar;105(3):501-23.
28. National Institute for Health and Care Excellence. NICE 2017. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs. Published 24 May 2017. Technology Appraisal Guidance [TA445]. <https://www.nice.org.uk/guidance/TA445/chapter/1-Recommendations>. Accessed August 2017.
29. National Institute for Health and Care Excellence. NICE 2009. Rheumatoid Arthritis in Adults: Management. Published 25 February 2009. Clinical Guideline [CG79]. <https://www.nice.org.uk/guidance/cg79/resources/rheumatoid-arthritis-in-adults-management-pdf-975636823525>.

30. National Institute for Health and Care Excellence. NICE 2010. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after failure of a TNF inhibitor. Published 10 October 2012. Clinical Guideline [TA195]. <https://www.nice.org.uk/guidance/ta195/resources/adalimumab-etanercept-infliximab-rituximab-and-abatacept-for-the-treatment-of-rheumatoid-arthritis-after-the-failure-of-a-tnf-inhibitor-pdf-82598558287813>.
31. Ward MM, Guthri LC, Alba MI. Rheumatoid Arthritis Response Criteria And Patient-Reported Improvement in Arthritis Activity: Is an ACR20 Response Meaningful to Patients”. *Arthritis Rheumatol.* 2014 Sep; 66(9): 2339–2343. doi: 10.1002/art.38705
32. National Institute for Health and Care Excellence. NICE 2008. Infliximab for the treatment of adults with psoriasis. Published 23 January 2008. Technology Appraisal Guidance [TA134]. <https://www.nice.org.uk/guidance/ta134/resources/infliximab-for-the-treatment-of-adults-with-psoriasis-pdf-82598193811141>.
33. Smith CH, Jabbar-Lopez ZK, Yiu ZK, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. *Br J Dermatol.* 2017 Sep;177(3):628-636. doi: 10.1111/bjd.15665.
34. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. *Am J Ophthalmol.* 2000 Oct;130(4):492-513.
35. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. *Ophthalmology.* 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.opthta.2013.09.048.
36. Minor DR, Chin K, Sashani-Sabet M, et al. Infliximab in the treatment of anti-CTLA4 antibody (Ipilimumab) induced immune-related colitis. *Cancer Biotherapy & Radiopharmaceuticals.* 2009 June; 24 (3). <https://doi.org/10.1089/cbr.2008.0607>
37. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. *Translational Lung Cancer Research.* 2015;4(5):560-575. doi:10.3978/j.issn.2218-6751.2015.06.06. Appendix 1 – Covered Diagnosis Codes
38. Lichtenstein GR, Loftus EV, Isaacs KI, et al. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. *Am J Gastroenterol* 2018; 113:481–517; doi: 10.1038/ajg.2018.27
39. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. *Arthritis & Rheumatology.* Vol. 0, No. 0, Month 2018, pp 1–28 DOI 10.1002/art.40726
40. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol.* 2019 Feb 13. pii: S0190-9622(18)33001-9. <https://doi.org/10.1016/j.jaad.2018.11.057>.
41. American Academy of Dermatology Work Group, Menter A, Korman NJ, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. *J Am Acad Dermatol.* 2011 Jul;65(1):137-74.

42. Fahrenbruch R, Kintzel P, Bott AM, et al. Dose Rounding of Biologic and Cytotoxic Anticancer Agents: A Position Statement of the Hematology/Oncology Pharmacy Association. *J Oncol Pract.* 2018 Mar;14(3):e130-e136.
43. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Infliximab. National Comprehensive Cancer Network, 2021. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed July 2021.
44. Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, et al. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. *Lancet Gastroenterol Hepatol.* 2018 Jun;3(6):404-412.
45. Milassin A, Fabian A, Molnar T. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. *Therap Adv Gastroenterol.* 2019; 12: 1756284819842748.
46. Glintborg B, Sørensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. *Ann Rheum Dis.* 2017 Aug;76(8):1426-1431.
47. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. *Ann Rheum Dis.* 2017 Feb;76(2):355-363.
48. Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. *Ann Rheum Dis.* 2017 Feb;76(2):346-354.
49. Jorgensen KK, Olcen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. *Lancet.* 2017 Jun 10;389(10086):2304-2316.
50. Goll GL, Jørgensen KK, Sexton J, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. *J Intern Med.* 2019 Jun;285(6):653-669.
51. Fahrenbruch R, Kintzel P, Bott AM, et al. Dose Rounding of Biologic and Cytotoxic Anticancer Agents: A Position Statement of the Hematology/Oncology Pharmacy Association. *J Oncol Pract.* 2018 Mar;14(3):e130-e136.
52. Celltrion. CT-P13 (infliximab biosimilar). Briefing document for the US FDA Arthritis Advisory Committee.

<http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM484860.pdf>.

53. Milassin A, Fabian A, Molnar T. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. *Therap Adv Gastroenterol*. 2019; 12: 1756284819842748.
54. Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, et al. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. *Lancet Gastroenterol Hepatol*. 2018 Jun;3(6):404-412.
55. Glintborg B, Sørensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. *Ann Rheum Dis*. 2017 Aug;76(8):1426-1431.
56. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. *Ann Rheum Dis*. 2017 Feb;76(2):355-363.
57. Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. *Ann Rheum Dis*. 2017 Feb;76(2):346-354.
58. Goll GL, Jørgensen KK, Sexton J, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. *J Intern Med*. 2019 Jun;285(6):653-669.
59. Choe JY, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. *Ann Rheum Dis*. 2017 Jan;76(1):58-64.
60. Smolen JS, Choe JY, Prodanovic N, et al. Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. *Rheumatology (Oxford)*. 2017 Oct; 56(10): 1771–1779.
61. Smolen JS, Choe JY, Prodanovic N, et al. Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. *Rheumatology (Oxford)*. 2017 Oct; 56(10): 1771–1779.
62. Choe J, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. *Ann Rheum Dis* 2017;76:58–64.
63. Smolen JS, Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, et al. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid

- arthritis: results of a randomised, double-blind, phase III transition study. *Ann Rheum Dis* 2017. E-pub ahead of print.
64. Chow V, Oh M, Gessner M, Fanjiang G. Pharmacokinetic similarity of ABP 710, a proposed biosimilar to infliximab: results from a randomized, single-blind, single-dose, parallel-group study in healthy subjects. *Clin Pharmacol Drug Dev*. 2019. doi:10.1002/cpdd.738
65. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Cell Transplantation Version 2.2021. National Comprehensive Cancer Network, 2021. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed July 2021.
66. Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. *Blood* 2004;104:649-65
67. Richard EG. (2021). Psoralen plus ultraviolet A (PUVA) photochemotherapy. In Elmets CA, Corona R (Eds.), *UptoDate*. Available from [https://www.uptodate.com/contents/psoralen-plus-ultraviolet-a-puva-photochemotherapy?sectionName=Skin%20cancer&search=psoriasis%20phototherapy&topicRef=5666&anchor=H31513976&source=see\\_link#H2099103](https://www.uptodate.com/contents/psoralen-plus-ultraviolet-a-puva-photochemotherapy?sectionName=Skin%20cancer&search=psoriasis%20phototherapy&topicRef=5666&anchor=H31513976&source=see_link#H2099103).
68. Honigsman H. (2020). UVB therapy (broadband and narrowband). In Elmets CA, Corona R (Eds.), *UptoDate*. Available from [https://www.uptodate.com/contents/uvb-therapy-broadband-and-narrowband?sectionName=SHORT-%20AND%20LONG-TERM%20ADVERSE%20EFFECTS&search=psoriasis%20phototherapy&topicRef=5666&anchor=H10844620&source=see\\_link#H10844627](https://www.uptodate.com/contents/uvb-therapy-broadband-and-narrowband?sectionName=SHORT-%20AND%20LONG-TERM%20ADVERSE%20EFFECTS&search=psoriasis%20phototherapy&topicRef=5666&anchor=H10844620&source=see_link#H10844627).
69. Smith CH, Yiu ZZN, Bale T, et al; British Association of Dermatologists' Clinical Standards Unit. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. *Br J Dermatol*. 2020 Oct;183(4):628-637. doi: 10.1111/bjd.19039.
70. Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. *J Am Acad Dermatol*. 2020 Jan;82(1):161-201. doi: 10.1016/j.jaad.2019.08.049.
71. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. *Ann Rheum Dis*. 2020 Jun;79(6):700-712. doi: 10.1136/annrheumdis-2020-217159.
72. Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite

- Psoriatic Disease Activity Index (CPDAI). *Arthritis Care Res (Hoboken)*. 2011 Nov;63 Suppl 11:S64-85. doi: 10.1002/acr.20577.
73. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatol*. 2019 Oct;71(10):1599-1613. doi: 10.1002/art.41042.
  74. Fraenkel L, Bartholomew JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care & Research* Vol. 0, No. 0, Month 2021, pp 1–16 DOI 10.1002/acr.24596
  75. Torres J, Bonovas S, Doherty G, et al. European Crohn's and Colitis Organisation [ECCO] Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. *Journal of Crohn's and Colitis*, 2020, 4–22 doi:10.1093/ecco-jcc/jjz180.
  76. Feurstein JD, Ho EY, Schmidt E, et al. American Gastroenterological Association Institute – AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. *Gastroenterology* 2021;160:2496–2508.
  77. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut* 2019;0:1–106. doi:10.1136/gutjnl-2019-318484.
  78. Panaccione R, Steinhart AH, Bressler B, et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. *Journal of the Canadian Association of Gastroenterology*, 2019, 2(3), e1–e34 doi: 10.1093/jcag/gwz019.
  79. National Institute for Health and Care Excellence. NICE 2013. Psoriasis. Published 06 August 2013. Quality standard [QS40]. <https://www.nice.org.uk/guidance/qs40>. Accessed June 2021.
  80. First Coast Service Options, Inc. Local Coverage Article: Billing and Coding: INFLIXIMAB (A57653). Centers for Medicare & Medicaid Services, Inc. Updated on 09/25/2020 with effective date 09/30/2020. Accessed July 2021.
  81. National Government Services, Inc. Local Coverage Article: Billing and Coding: INFLIXIMAB and biosimilars (A52423). Centers for Medicare & Medicaid Services, Inc. Updated on 4/23/2021 with effective date 5/1/2021. Accessed July 2021
  82. Palmetto GBA. Local Coverage Article: Billing and Coding: INFLIXIMAB (A56432). Centers for Medicare & Medicaid Services, Inc. Updated on 08/26/2020 with effective date 10/01/2020. Accessed July 2021.

## Appendix 1 – Covered Diagnosis Codes

| ICD-10  | ICD-10 Description                           |
|---------|--|
| D89.810 | Acute graft-versus host disease              |
| D89.812 | Acute on chronic graft-versus-host-disease   |
| D89.813 | Graft-versus-host disease unspecified        |
| H30.891 | Other chorioretinal inflammations, right eye |
| H30.892 | Other chorioretinal inflammations, left eye  |

**INFLIXIMAB (Remicade®; Inflectra™; Renflexis™; Avsola™)**  
**Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management



| ICD-10  | ICD-10 Description                                       |
|---------|--|
| H30.893 | Other chorioretinal inflammations, bilateral             |
| H30.899 | Other chorioretinal inflammations, unspecified eye       |
| H30.90  | Unspecified chorioretinal inflammation, unspecified eye  |
| H30.91  | Unspecified chorioretinal inflammation, right eye        |
| H30.92  | Unspecified chorioretinal inflammation, left eye         |
| H30.93  | Unspecified chorioretinal inflammation, bilateral        |
| H44.111 | Panuveitis, right eye                                    |
| H44.112 | Panuveitis, left eye                                     |
| H44.113 | Panuveitis, bilateral                                    |
| H44.119 | Panuveitis, unspecified eye                              |
| I30.8   | Other forms of acute pericarditis                        |
| I30.9   | Acute pericarditis, unspecified                          |
| I40.8   | Other acute myocarditis                                  |
| I40.9   | Acute myocarditis, unspecified                           |
| I44.0   | Atrioventricular block, first degree                     |
| I44.1   | Atrioventricular block, second degree                    |
| I44.2   | Atrioventricular block, complete                         |
| I44.30  | Unspecified atrioventricular block                       |
| I44.39  | Other atrioventricular block                             |
| I45.0   | Right fascicular block                                   |
| I45.2   | Bifascicular block                                       |
| I45.3   | Trifascicular block                                      |
| I45.4   | Nonspecific intraventricular block                       |
| I45.5   | Other specified heart block                              |
| I45.6   | Pre-excitation syndrome                                  |
| I45.9   | Conduction disorder, unspecified                         |
| I45.10  | Unspecified right bundle-branch block                    |
| I45.19  | Other right bundle-brand block                           |
| I45.81  | Long QT syndrome   |
| I45.89  | Other specified conduction disorders                     |
| I47.0   | Re-entry ventricular arrhythmia                          |
| I49.9   | Cardiac arrhythmia, unspecified                          |
| J70.2   | Acute drug-induced interstitial lung disorders           |
| J70.4   | Drug-induced interstitial lung disorders, unspecified    |
| K50.00  | Crohn's disease of small intestine without complications |

**INFLIXIMAB (Remicade®; Inflectra™; Renflexis™; Avsola™)  
Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management





| ICD-10  | ICD-10 Description   |
|---------|--|
| K50.011 | Crohn's disease of small intestine with rectal bleeding                          |
| K50.012 | Crohn's disease of small intestine with intestinal obstruction                   |
| K50.013 | Crohn's disease of small intestine with fistula                                  |
| K50.014 | Crohn's disease of small intestine with abscess                                  |
| K50.018 | Crohn's disease of small intestine with other complication                       |
| K50.019 | Crohn's disease of small intestine with unspecified complications                |
| K50.10  | Crohn's disease of large intestine without complications                         |
| K50.111 | Crohn's disease of large intestine with rectal bleeding                          |
| K50.112 | Crohn's disease of large intestine with intestinal obstruction                   |
| K50.113 | Crohn's disease of large intestine with fistula                                  |
| K50.114 | Crohn's disease of large intestine with abscess                                  |
| K50.118 | Crohn's disease of large intestine with other complication                       |
| K50.119 | Crohn's disease of large intestine with unspecified complications                |
| K50.80  | Crohn's disease of both small and large intestine without complications          |
| K50.811 | Crohn's disease of both small and large intestine with rectal bleeding           |
| K50.812 | Crohn's disease of both small and large intestine with intestinal obstruction    |
| K50.813 | Crohn's disease of both small and large intestine with fistula                   |
| K50.814 | Crohn's disease of both small and large intestine with abscess                   |
| K50.818 | Crohn's disease of both small and large intestine with other complication        |
| K50.819 | Crohn's disease of both small and large intestine with unspecified complications |
| K50.90  | Crohn's disease, unspecified, without complications                              |
| K50.911 | Crohn's disease, unspecified, with rectal bleeding                               |
| K50.912 | Crohn's disease, unspecified, with intestinal obstruction                        |
| K50.913 | Crohn's disease, unspecified, with fistula                                       |
| K50.914 | Crohn's disease, unspecified, with abscess                                       |
| K50.918 | Crohn's disease, unspecified, with other complication                            |
| K50.919 | Crohn's disease, unspecified, with unspecified complications                     |
| K51.00  | Ulcerative (chronic) pancolitis without complications                            |
| K51.011 | Ulcerative (chronic) pancolitis with rectal bleeding                             |
| K51.012 | Ulcerative (chronic) pancolitis with intestinal obstruction                      |
| K51.013 | Ulcerative (chronic) pancolitis with fistula                                     |
| K51.014 | Ulcerative (chronic) pancolitis with abscess                                     |
| K51.018 | Ulcerative (chronic) pancolitis with other complication                          |
| K51.019 | Ulcerative (chronic) pancolitis with unspecified complications                   |
| K51.20  | Ulcerative (chronic) proctitis without complications                             |

**INFLIXIMAB (Remicade®; Inflectra™; Renflexis™; Avsola™)**  
**Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management



| ICD-10  | ICD-10 Description   |
|---------|--|
| K51.211 | Ulcerative (chronic) proctitis with rectal bleeding                  |
| K51.212 | Ulcerative (chronic) proctitis with intestinal obstruction           |
| K51.213 | Ulcerative (chronic) proctitis with fistula                          |
| K51.214 | Ulcerative (chronic) proctitis with abscess                          |
| K51.218 | Ulcerative (chronic) proctitis with other complication               |
| K51.219 | Ulcerative (chronic) proctitis with unspecified complications        |
| K51.30  | Ulcerative (chronic) rectosigmoiditis without complications          |
| K51.311 | Ulcerative (chronic) rectosigmoiditis with rectal bleeding           |
| K51.312 | Ulcerative (chronic) rectosigmoiditis with intestinal obstruction    |
| K51.313 | Ulcerative (chronic) rectosigmoiditis with fistula                   |
| K51.314 | Ulcerative (chronic) rectosigmoiditis with abscess                   |
| K51.318 | Ulcerative (chronic) rectosigmoiditis with other complication        |
| K51.319 | Ulcerative (chronic) rectosigmoiditis with unspecified complications |
| K51.50  | Left sided colitis without complications                             |
| K51.511 | Left sided colitis with rectal bleeding                              |
| K51.512 | Left sided colitis with intestinal obstruction                       |
| K51.513 | Left sided colitis with fistula                                      |
| K51.514 | Left sided colitis with abscess                                      |
| K51.518 | Left sided colitis with other complication                           |
| K51.519 | Left sided colitis with unspecified complications                    |
| K51.80  | Other ulcerative colitis without complications                       |
| K51.811 | Other ulcerative colitis with rectal bleeding                        |
| K51.812 | Other ulcerative colitis with intestinal obstruction                 |
| K51.813 | Other ulcerative colitis with fistula                                |
| K51.814 | Other ulcerative colitis with abscess                                |
| K51.818 | Other ulcerative colitis with other complication                     |
| K51.819 | Other ulcerative colitis with unspecified complications              |
| K51.90  | Ulcerative colitis, unspecified, without complications               |
| K51.911 | Ulcerative colitis, unspecified with rectal bleeding                 |
| K51.912 | Ulcerative colitis, unspecified with intestinal obstruction          |
| K51.913 | Ulcerative colitis, unspecified with fistula                         |
| K51.914 | Ulcerative colitis, unspecified with abscess                         |
| K51.918 | Ulcerative colitis, unspecified with other complication              |
| K51.919 | Ulcerative colitis, unspecified with unspecified complications       |
| K52.1   | Toxic gastroenteritis and colitis                                    |

**INFLIXIMAB (Remicade®; Inflectra™; Renflexis™; Avsola™)**  
**Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management



| ICD-10  | ICD-10 Description  |
|---------|---|
| L40.0   | Psoriasis vulgaris  |
| L40.50  | Arthropathic psoriasis, unspecified   |
| L40.51  | Distal interphalangeal psoriatic arthropathy                                    |
| L40.52  | Psoriatic arthritis mutilans  |
| L40.53  | Psoriatic spondylitis   |
| L40.59  | Other psoriatic arthropathy   |
| M05.10  | Rheumatoid lung disease with rheumatoid arthritis of unspecified site           |
| M05.111 | Rheumatoid lung disease with rheumatoid arthritis of right shoulder             |
| M05.112 | Rheumatoid lung disease with rheumatoid arthritis of left shoulder              |
| M05.119 | Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder       |
| M05.121 | Rheumatoid lung disease with rheumatoid arthritis of right elbow                |
| M05.122 | Rheumatoid lung disease with rheumatoid arthritis of left elbow                 |
| M05.129 | Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow          |
| M05.131 | Rheumatoid lung disease with rheumatoid arthritis of right wrist                |
| M05.132 | Rheumatoid lung disease with rheumatoid arthritis of left wrist                 |
| M05.139 | Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist          |
| M05.141 | Rheumatoid lung disease with rheumatoid arthritis of right hand                 |
| M05.142 | Rheumatoid lung disease with rheumatoid arthritis of left hand                  |
| M05.149 | Rheumatoid lung disease with rheumatoid arthritis of unspecified hand           |
| M05.151 | Rheumatoid lung disease with rheumatoid arthritis of right hip                  |
| M05.152 | Rheumatoid lung disease with rheumatoid arthritis of left hip                   |
| M05.159 | Rheumatoid lung disease with rheumatoid arthritis of unspecified hip            |
| M05.161 | Rheumatoid lung disease with rheumatoid arthritis of right knee                 |
| M05.162 | Rheumatoid lung disease with rheumatoid arthritis of left knee                  |
| M05.169 | Rheumatoid lung disease with rheumatoid arthritis of unspecified knee           |
| M05.171 | Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot       |
| M05.172 | Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot        |
| M05.179 | Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot |
| M05.19  | Rheumatoid lung disease with rheumatoid arthritis of multiple sites             |
| M05.20  | Rheumatoid vasculitis with rheumatoid arthritis of unspecified site             |
| M05.211 | Rheumatoid vasculitis with rheumatoid arthritis of right shoulder               |
| M05.212 | Rheumatoid vasculitis with rheumatoid arthritis of left shoulder                |
| M05.219 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder         |
| M05.221 | Rheumatoid vasculitis with rheumatoid arthritis of right elbow                  |
| M05.222 | Rheumatoid vasculitis with rheumatoid arthritis of left elbow                   |

**INFLIXIMAB (Remicade®; Inflectra™; Renflexis™; Avsola™)**  
**Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management



| ICD-10  | ICD-10 Description  |
|---------|---|
| M05.229 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow          |
| M05.231 | Rheumatoid vasculitis with rheumatoid arthritis of right wrist                |
| M05.232 | Rheumatoid vasculitis with rheumatoid arthritis of left wrist                 |
| M05.239 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist          |
| M05.241 | Rheumatoid vasculitis with rheumatoid arthritis of right hand                 |
| M05.242 | Rheumatoid vasculitis with rheumatoid arthritis of left hand                  |
| M05.249 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand           |
| M05.251 | Rheumatoid vasculitis with rheumatoid arthritis of right hip                  |
| M05.252 | Rheumatoid vasculitis with rheumatoid arthritis of left hip                   |
| M05.259 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip            |
| M05.261 | Rheumatoid vasculitis with rheumatoid arthritis of right knee                 |
| M05.262 | Rheumatoid vasculitis with rheumatoid arthritis of left knee                  |
| M05.269 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee           |
| M05.271 | Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot       |
| M05.272 | Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot        |
| M05.279 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot |
| M05.29  | Rheumatoid vasculitis with rheumatoid arthritis of multiple sites             |
| M05.30  | Rheumatoid heart disease with rheumatoid arthritis of unspecified site        |
| M05.311 | Rheumatoid heart disease with rheumatoid arthritis of right shoulder          |
| M05.312 | Rheumatoid heart disease with rheumatoid arthritis of left shoulder           |
| M05.319 | Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder    |
| M05.321 | Rheumatoid heart disease with rheumatoid arthritis of right elbow             |
| M05.322 | Rheumatoid heart disease with rheumatoid arthritis of left elbow              |
| M05.329 | Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow       |
| M05.331 | Rheumatoid heart disease with rheumatoid arthritis of right wrist             |
| M05.332 | Rheumatoid heart disease with rheumatoid arthritis of left wrist              |
| M05.339 | Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist       |
| M05.341 | Rheumatoid heart disease with rheumatoid arthritis of right hand              |
| M05.342 | Rheumatoid heart disease with rheumatoid arthritis of left hand               |
| M05.349 | Rheumatoid heart disease with rheumatoid arthritis of unspecified hand        |
| M05.351 | Rheumatoid heart disease with rheumatoid arthritis of right hip               |
| M05.352 | Rheumatoid heart disease with rheumatoid arthritis of left hip                |
| M05.359 | Rheumatoid heart disease with rheumatoid arthritis of unspecified hip         |
| M05.361 | Rheumatoid heart disease with rheumatoid arthritis of right knee              |
| M05.362 | Rheumatoid heart disease with rheumatoid arthritis of left knee               |

**INFLIXIMAB (Remicade®; Inflectra™; Renflexis™; Avsola™)**  
**Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management



| ICD-10  | ICD-10 Description   |
|---------|--|
| M05.369 | Rheumatoid heart disease with rheumatoid arthritis of unspecified knee           |
| M05.371 | Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot       |
| M05.372 | Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot        |
| M05.379 | Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot |
| M05.39  | Rheumatoid heart disease with rheumatoid arthritis of multiple sites             |
| M05.40  | Rheumatoid myopathy with rheumatoid arthritis of unspecified site                |
| M05.411 | Rheumatoid myopathy with rheumatoid arthritis of right shoulder                  |
| M05.412 | Rheumatoid myopathy with rheumatoid arthritis of left shoulder                   |
| M05.419 | Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder            |
| M05.421 | Rheumatoid myopathy with rheumatoid arthritis of right elbow                     |
| M05.422 | Rheumatoid myopathy with rheumatoid arthritis of left elbow                      |
| M05.429 | Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow               |
| M05.431 | Rheumatoid myopathy with rheumatoid arthritis of right wrist                     |
| M05.432 | Rheumatoid myopathy with rheumatoid arthritis of left wrist                      |
| M05.439 | Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist               |
| M05.441 | Rheumatoid myopathy with rheumatoid arthritis of right hand                      |
| M05.442 | Rheumatoid myopathy with rheumatoid arthritis of left hand                       |
| M05.449 | Rheumatoid myopathy with rheumatoid arthritis of unspecified hand                |
| M05.451 | Rheumatoid myopathy with rheumatoid arthritis of right hip                       |
| M05.452 | Rheumatoid myopathy with rheumatoid arthritis of left hip                        |
| M05.459 | Rheumatoid myopathy with rheumatoid arthritis of unspecified hip                 |
| M05.461 | Rheumatoid myopathy with rheumatoid arthritis of right knee                      |
| M05.462 | Rheumatoid myopathy with rheumatoid arthritis of left knee                       |
| M05.469 | Rheumatoid myopathy with rheumatoid arthritis of unspecified knee                |
| M05.471 | Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot            |
| M05.472 | Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot             |
| M05.479 | Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot      |
| M05.49  | Rheumatoid myopathy with rheumatoid arthritis of multiple sites                  |
| M05.50  | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site          |
| M05.511 | Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder            |
| M05.512 | Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder             |
| M05.519 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder      |
| M05.521 | Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow               |
| M05.522 | Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow                |
| M05.529 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow         |

**INFLIXIMAB (Remicade®; Inflectra™; Renflexis™; Avsola™)**  
**Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management



| ICD-10  | ICD-10 Description  |
|---------|---|
| M05.531 | Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist                        |
| M05.532 | Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist                         |
| M05.539 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist                  |
| M05.541 | Rheumatoid polyneuropathy with rheumatoid arthritis of right hand                         |
| M05.542 | Rheumatoid polyneuropathy with rheumatoid arthritis of left hand                          |
| M05.549 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand                   |
| M05.551 | Rheumatoid polyneuropathy with rheumatoid arthritis of right hip                          |
| M05.552 | Rheumatoid polyneuropathy with rheumatoid arthritis of left hip                           |
| M05.559 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip                    |
| M05.561 | Rheumatoid polyneuropathy with rheumatoid arthritis of right knee                         |
| M05.562 | Rheumatoid polyneuropathy with rheumatoid arthritis of left knee                          |
| M05.569 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee                   |
| M05.571 | Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot               |
| M05.572 | Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot                |
| M05.579 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot         |
| M05.59  | Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites                     |
| M05.60  | Rheumatoid arthritis of unspecified site with involvement of other organs and systems     |
| M05.611 | Rheumatoid arthritis of right shoulder with involvement of other organs and systems       |
| M05.612 | Rheumatoid arthritis of left shoulder with involvement of other organs and systems        |
| M05.619 | Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems |
| M05.621 | Rheumatoid arthritis of right elbow with involvement of other organs and systems          |
| M05.622 | Rheumatoid arthritis of left elbow with involvement of other organs and systems           |
| M05.629 | Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems    |
| M05.631 | Rheumatoid arthritis of right wrist with involvement of other organs and systems          |
| M05.632 | Rheumatoid arthritis of left wrist with involvement of other organs and systems           |
| M05.639 | Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems    |
| M05.641 | Rheumatoid arthritis of right hand with involvement of other organs and systems           |
| M05.642 | Rheumatoid arthritis of left hand with involvement of other organs and systems            |
| M05.649 | Rheumatoid arthritis of unspecified hand with involvement of other organs and systems     |
| M05.651 | Rheumatoid arthritis of right hip with involvement of other organs and systems            |
| M05.652 | Rheumatoid arthritis of left hip with involvement of other organs and systems             |
| M05.659 | Rheumatoid arthritis of unspecified hip with involvement of other organs and systems      |
| M05.661 | Rheumatoid arthritis of right knee with involvement of other organs and systems           |
| M05.662 | Rheumatoid arthritis of left knee with involvement of other organs and systems            |
| M05.669 | Rheumatoid arthritis of unspecified knee with involvement of other organs and systems     |

**INFLIXIMAB (Remicade®; Inflectra™; Renflexis™; Avsola™)**

**Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management



| ICD-10  | ICD-10 Description   |
|---------|--|
| M05.671 | Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems                |
| M05.672 | Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems                 |
| M05.679 | Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems          |
| M05.69  | Rheumatoid arthritis of multiple sites with involvement of other organs and systems                      |
| M05.7A  | Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement |
| M05.711 | Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement       |
| M05.712 | Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement        |
| M05.719 | Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement |
| M05.721 | Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement          |
| M05.722 | Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement           |
| M05.729 | Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement    |
| M05.731 | Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement          |
| M05.732 | Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement           |
| M05.739 | Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement    |
| M05.741 | Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement           |
| M05.742 | Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement            |
| M05.749 | Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement     |
| M05.751 | Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement            |
| M05.752 | Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement             |
| M05.759 | Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement      |
| M05.761 | Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement           |
| M05.762 | Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement            |
| M05.769 | Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement     |
| M05.771 | Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement |
| M05.772 | Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement  |

**INFLIXIMAB (Remicade®; Inflectra™; Renflexis™; Avsola™)**  
**Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management



| ICD-10  | ICD-10 Description   |
|---------|--|
| M05.779 | Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement |
| M05.79  | Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement             |
| M05.8A  | Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement       |
| M05.811 | Other rheumatoid arthritis with rheumatoid factor of right shoulder  |
| M05.812 | Other rheumatoid arthritis with rheumatoid factor of left shoulder   |
| M05.819 | Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder                                      |
| M05.821 | Other rheumatoid arthritis with rheumatoid factor of right elbow   |
| M05.822 | Other rheumatoid arthritis with rheumatoid factor of left elbow  |
| M05.829 | Other rheumatoid arthritis with rheumatoid factor of unspecified elbow   |
| M05.831 | Other rheumatoid arthritis with rheumatoid factor of right wrist   |
| M05.832 | Other rheumatoid arthritis with rheumatoid factor of left wrist  |
| M05.839 | Other rheumatoid arthritis with rheumatoid factor of unspecified wrist   |
| M05.841 | Other rheumatoid arthritis with rheumatoid factor of right hand  |
| M05.842 | Other rheumatoid arthritis with rheumatoid factor of left hand   |
| M05.849 | Other rheumatoid arthritis with rheumatoid factor of unspecified hand  |
| M05.851 | Other rheumatoid arthritis with rheumatoid factor of right hip   |
| M05.852 | Other rheumatoid arthritis with rheumatoid factor of left hip  |
| M05.859 | Other rheumatoid arthritis with rheumatoid factor of unspecified hip   |
| M05.861 | Other rheumatoid arthritis with rheumatoid factor of right knee  |
| M05.862 | Other rheumatoid arthritis with rheumatoid factor of left knee   |
| M05.869 | Other rheumatoid arthritis with rheumatoid factor of unspecified knee  |
| M05.871 | Other rheumatoid arthritis with rheumatoid factor of right ankle and foot                                      |
| M05.872 | Other rheumatoid arthritis with rheumatoid factor of left ankle and foot                                       |
| M05.879 | Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot                                |
| M05.89  | Other rheumatoid arthritis with rheumatoid factor of multiple sites  |
| M05.9   | Rheumatoid arthritis with rheumatoid factor, unspecified   |
| M06.0A  | Rheumatoid arthritis without rheumatoid factor, other specified site   |
| M06.011 | Rheumatoid arthritis without rheumatoid factor, right shoulder   |
| M06.012 | Rheumatoid arthritis without rheumatoid factor, left shoulder  |
| M06.019 | Rheumatoid arthritis without rheumatoid factor, unspecified shoulder   |
| M06.021 | Rheumatoid arthritis without rheumatoid factor, right elbow  |
| M06.022 | Rheumatoid arthritis without rheumatoid factor, left elbow   |

**INFLIXIMAB (Remicade®; Inflectra™; Renflexis™; Avsola™)**  
**Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management





| ICD-10  | ICD-10 Description   |
|---------|--|
| M06.029 | Rheumatoid arthritis without rheumatoid factor, unspecified elbow          |
| M06.031 | Rheumatoid arthritis without rheumatoid factor, right wrist                |
| M06.032 | Rheumatoid arthritis without rheumatoid factor, left wrist                 |
| M06.039 | Rheumatoid arthritis without rheumatoid factor, unspecified wrist          |
| M06.041 | Rheumatoid arthritis without rheumatoid factor, right hand                 |
| M06.042 | Rheumatoid arthritis without rheumatoid factor, left hand                  |
| M06.049 | Rheumatoid arthritis without rheumatoid factor, unspecified hand           |
| M06.051 | Rheumatoid arthritis without rheumatoid factor, right hip                  |
| M06.052 | Rheumatoid arthritis without rheumatoid factor, left hip                   |
| M06.059 | Rheumatoid arthritis without rheumatoid factor, unspecified hip            |
| M06.061 | Rheumatoid arthritis without rheumatoid factor, right knee                 |
| M06.062 | Rheumatoid arthritis without rheumatoid factor, left knee                  |
| M06.069 | Rheumatoid arthritis without rheumatoid factor, unspecified knee           |
| M06.071 | Rheumatoid arthritis without rheumatoid factor, right ankle and foot       |
| M06.072 | Rheumatoid arthritis without rheumatoid factor, left ankle and foot        |
| M06.079 | Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot |
| M06.08  | Rheumatoid arthritis without rheumatoid factor, vertebrae                  |
| M06.09  | Rheumatoid arthritis without rheumatoid factor, multiple sites             |
| M06.4   | Inflammatory polyarthropathy   |
| M06.8A  | Other specified rheumatoid arthritis, other specified site                 |
| M06.811 | Other specified rheumatoid arthritis, right shoulder                       |
| M06.812 | Other specified rheumatoid arthritis, left shoulder                        |
| M06.819 | Other specified rheumatoid arthritis, unspecified shoulder                 |
| M06.821 | Other specified rheumatoid arthritis, right elbow                          |
| M06.822 | Other specified rheumatoid arthritis, left elbow                           |
| M06.829 | Other specified rheumatoid arthritis, unspecified elbow                    |
| M06.831 | Other specified rheumatoid arthritis, right wrist                          |
| M06.832 | Other specified rheumatoid arthritis, left wrist                           |
| M06.839 | Other specified rheumatoid arthritis, unspecified wrist                    |
| M06.841 | Other specified rheumatoid arthritis, right hand                           |
| M06.842 | Other specified rheumatoid arthritis, left hand                            |
| M06.849 | Other specified rheumatoid arthritis, unspecified hand                     |
| M06.851 | Other specified rheumatoid arthritis, right hip                            |
| M06.852 | Other specified rheumatoid arthritis, left hip                             |
| M06.859 | Other specified rheumatoid arthritis, unspecified hip                      |

**INFLIXIMAB (Remicade®; Inflectra™; Renflexis™; Avsola™)**  
**Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management



| ICD-10  | ICD-10 Description   |
|---------|--|
| M06.861 | Other specified rheumatoid arthritis, right knee                 |
| M06.862 | Other specified rheumatoid arthritis, left knee                  |
| M06.869 | Other specified rheumatoid arthritis, unspecified knee           |
| M06.871 | Other specified rheumatoid arthritis, right ankle and foot       |
| M06.872 | Other specified rheumatoid arthritis, left ankle and foot        |
| M06.879 | Other specified rheumatoid arthritis, unspecified ankle and foot |
| M06.88  | Other specified rheumatoid arthritis, vertebrae                  |
| M06.89  | Other specified rheumatoid arthritis, multiple sites             |
| M06.9   | Rheumatoid arthritis, unspecified                                |
| M35.2   | Behçet's disease   |
| M45.0   | Ankylosing spondylitis of multiple sites in spine                |
| M45.1   | Ankylosing spondylitis of occipito-atlanto-axial region          |
| M45.2   | Ankylosing spondylitis of cervical region                        |
| M45.3   | Ankylosing spondylitis of cervicothoracic region                 |
| M45.4   | Ankylosing spondylitis of thoracic region                        |
| M45.5   | Ankylosing spondylitis of thoracolumbar region                   |
| M45.6   | Ankylosing spondylitis lumbar region                             |
| M45.7   | Ankylosing spondylitis of lumbosacral region                     |
| M45.8   | Ankylosing spondylitis sacral and sacrococcygeal region          |
| M45.9   | Ankylosing spondylitis of unspecified sites in spine             |
| M60.80  | Other myositis, unspecified                                      |
| M60.811 | Other myositis, right shoulder                                   |
| M60.812 | Other myositis, left shoulder                                    |
| M60.819 | Other myositis, unspecified shoulder                             |
| M60.821 | Other myositis, right upper arm                                  |
| M60.822 | Other myositis, left upper arm                                   |
| M60.829 | Other myositis, unspecified upper arm                            |
| M60.831 | Other myositis, right forearm                                    |
| M60.832 | Other myositis, left forearm                                     |
| M60.839 | Other myositis, unspecified forearm                              |
| M60.841 | Other myositis, right hand                                       |
| M60.842 | Other myositis, left hand  |
| M60.849 | Other myositis, unspecified hand                                 |
| M60.851 | Other myositis, right thigh                                      |
| M60.852 | Other myositis, left thigh                                       |

**INFLIXIMAB (Remicade®; Inflectra™; Renflexis™; Avsola™)**  
**Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2021, Magellan Rx Management



| ICD-10  | ICD-10 Description                            |
|---------|---|
| M60.859 | Other myositis, unspecified thigh             |
| M60.861 | Other myositis, right lower leg               |
| M60.862 | Other myositis, left lower leg                |
| M60.869 | Other myositis, unspecified lower leg         |
| M60.871 | Other myositis, right ankle and foot          |
| M60.872 | Other myositis, left ankle and foot           |
| M60.879 | Other myositis, unspecified ankle and foot    |
| M60.88  | Other myositis, other site                    |
| M60.89  | Other myositis, multiple sites                |
| M60.9   | Myositis, unspecified                         |
| M79.10  | Myalgia, unspecified                          |
| N17.8   | Other acute kidney failure                    |
| N17.9   | Acute kidney failure, unspecified             |
| R19.7   | Diarrhea, unspecified                         |
| T86.09  | Other complications of bone marrow transplant |
| Z94.81  | Bone marrow transplant status                 |

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA):

|   |   |
|---|---|
| <b>Jurisdiction(s):</b> N,9   | <b>NCD/LCD/LCA Document (s):</b> A57653 |
| <a href="https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleid=57653&amp;ver=10&amp;bc=CAAAAAAAAAAAAA">https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleid=57653&amp;ver=10&amp;bc=CAAAAAAAAAAAAA</a> |   |

|   |   |
|---|---|
| <b>Jurisdiction(s):</b> M,11  | <b>NCD/LCD/LCA Document (s):</b> A56432 |
| <a href="https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleid=56432&amp;ver=10&amp;bc=CAAAAAAAAAAAAA">https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleid=56432&amp;ver=10&amp;bc=CAAAAAAAAAAAAA</a> |   |

|   |   |
|---|---|
| <b>Jurisdiction(s):</b> 6,K   | <b>NCD/LCD/LCA Document (s):</b> A52423 |
| <a href="https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleid=52423&amp;ver=10&amp;bc=CAAAAAAAAAAAAA">https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleid=52423&amp;ver=10&amp;bc=CAAAAAAAAAAAAA</a> |   |

| <b>Medicare Part B Administrative Contractor (MAC) Jurisdictions</b> |   |   |
|--|---|---|
| <b>Jurisdiction</b>  | <b>Applicable State/US Territory</b>  | <b>Contractor</b>                                 |
| E (1)  | CA, HI, NV, AS, GU, CNMI  | Noridian Healthcare Solutions, LLC                |
| F (2 & 3)  | AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ  | Noridian Healthcare Solutions, LLC                |
| 5  | KS, NE, IA, MO  | Wisconsin Physicians Service Insurance Corp (WPS) |
| 6  | MN, WI, IL  | National Government Services, Inc. (NGS)          |
| H (4 & 7)  | LA, AR, MS, TX, OK, CO, NM  | Novitas Solutions, Inc.                           |
| 8  | MI, IN  | Wisconsin Physicians Service Insurance Corp (WPS) |
| N (9)  | FL, PR, VI  | First Coast Service Options, Inc.                 |
| J (10)   | TN, GA, AL  | Palmetto GBA, LLC                                 |
| M (11)   | NC, SC, WV, VA (excluding below)  | Palmetto GBA, LLC                                 |
| L (12)   | DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA) | Novitas Solutions, Inc.                           |
| K (13 & 14)  | NY, CT, MA, RI, VT, ME, NH  | National Government Services, Inc. (NGS)          |
| 15   | KY, OH  | CGS Administrators, LLC                           |